SRC and neoplasm: In 5-fluorouracil (5FU)-resistant human pancreatic cells, inhibition of the activity of SRC kinases by PP2 restored cellular sensitivity to 5-FU, and combined treatment of 5FU-resistant pancreatic cells with 5-FU plus PP2 inhibited 5-FU activation of the EGFR/SRC/AKT pathway as well as tumor growth and distant metastasis in vivo [80].